MCET (MultiCell Technologies) FCF Margin %: -40.51% (As of Aug. 2015)


What is MultiCell Technologies FCF Margin %?

MultiCell Technologies MCET -90.00% FCF Margin % is -40.51% as of Aug. 2015.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MultiCell Technologies's Free Cash Flow for the three months ended in Aug. 2015 was $-0.08 Mil. MultiCell Technologies's Revenue for the three months ended in Aug. 2015 was $0.20 Mil. Therefore, MultiCell Technologies's FCF Margin % for the quarter that ended in Aug. 2015 was -40.51%.

As of today, MultiCell Technologies's current FCF Yield % is -6,207,400.00%.

The historical rank and industry rank for MultiCell Technologies's FCF Margin % or its related term are showing as below:

MCET' s FCF Margin % Range Over the Past 10 Years
Min: -24.47   Med: 0   Max: 0
Current: -24.47

MCET's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -82.65 vs MCET: -24.47

MultiCell Technologies FCF Margin % Related Terms

MultiCell Technologies FCF Margin % Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies FCF Margin % Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -755.56 -3,069.39 -1,816.33 -2,553.06 -2,220.41

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,783.33 -2,491.67 -1,050.00 52.39 -40.51

MCET vs ERGO, OPLI, GLAG: FCF Margin % Comparison

For the Biotechnology subindustry, MultiCell Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MultiCell Technologies FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's FCF Margin % falls into.


MultiCell Technologies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

MultiCell Technologies's FCF Margin for the fiscal year that ended in Nov. 2014 is calculated as

FCF Margin=Free Cash Flow (A: Nov. 2014 )/Revenue (A: Nov. 2014 )
=-1.088/0.049
=-2,220.41 %

MultiCell Technologies's FCF Margin for the quarter that ended in Aug. 2015 is calculated as

FCF Margin=Free Cash Flow (Q: Aug. 2015 )/Revenue (Q: Aug. 2015 )
=-0.079/0.195
=-40.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -40.51% mean?
MultiCell Technologies (MCET) has a FCF Margin % of -40.51% as of Aug. 2015. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MultiCell Technologies and its competitors.
Is MultiCell Technologies' FCF Margin % too high?
MultiCell Technologies' current FCF Margin % is -40.51%.
How does MultiCell Technologies' FCF Margin % compare to ERGO and OPLI?
MultiCell Technologies' FCF Margin % of -40.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MultiCell Technologies and its competitors. MultiCell Technologies's current FCF Margin % is -40.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current FCF Margin % of -40.51%. The current FCF Margin % is -40.51%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current FCF Margin % is -40.51% as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.